These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8054286)

  • 1. Management of ovarian cancer: referral to a multidisciplinary team matters.
    Junor EJ; Hole DJ; Gillis CR
    Br J Cancer; 1994 Aug; 70(2):363-70. PubMed ID: 8054286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.
    Junor EJ; Hole DJ; McNulty L; Mason M; Young J
    Br J Obstet Gynaecol; 1999 Nov; 106(11):1130-6. PubMed ID: 10549956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival in ovarian cancer in Wales: Prior to introduction of all Wales guidelines.
    Shylasree TS; Howells RE; Lim K; Jones PW; Fiander A; Adams M; Evans AS;
    Int J Gynecol Cancer; 2006; 16(5):1770-6. PubMed ID: 17009970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
    Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
    Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma.
    Kehoe S; Powell J; Wilson S; Woodman C
    Br J Cancer; 1994 Nov; 70(5):1014-7. PubMed ID: 7947077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of palliative care referral in ovarian cancer: A single institution 5 year retrospective analysis.
    Nitecki R; Diver EJ; Kamdar MM; Boruta DM; Del Carmen MC; Clark RM; Goodman A; Schorge JO; Growdon WB
    Gynecol Oncol; 2018 Mar; 148(3):521-526. PubMed ID: 29395315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of women with apparent early ovarian cancer in the south-west region of England.
    Olaitan A; Murdoch J; Weeks J; James J; Howe K
    J Obstet Gynaecol; 2002 Jul; 22(4):394-8. PubMed ID: 12521463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective.
    Elstrand MB; Sandstad B; Oksefjell H; Davidson B; Tropé CG
    Acta Obstet Gynecol Scand; 2012 Mar; 91(3):308-17. PubMed ID: 22050605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.
    Foote J; Lopez-Acevedo M; Samsa G; Lee PS; Kamal AH; Alvarez Secord A; Havrilesky LJ
    Int J Gynecol Cancer; 2018 Feb; 28(2):302-307. PubMed ID: 29360690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
    Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging procedures, clinical management, and survival outcome for ovarian carcinoma.
    Hand R; Fremgen A; Chmiel JS; Recant W; Berk R; Sylvester J; Sener S
    JAMA; 1993 Mar; 269(9):1119-22. PubMed ID: 8433466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in stage I ovarian carcinoma.
    Vergote I
    Verh K Acad Geneeskd Belg; 2001; 63(3):257-71; discussion 272-6. PubMed ID: 11499346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
    Akahira JI; Yoshikawa H; Shimizu Y; Tsunematsu R; Hirakawa T; Kuramoto H; Shiromizu K; Kuzuya K; Kamura T; Kikuchi Y; Kodama S; Yamamoto K; Sato S
    Gynecol Oncol; 2001 Jun; 81(3):398-403. PubMed ID: 11371128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic factors of epithelial ovarian cancer in young women].
    Zhang R; Wu LY; Zhang WH; Li HJ; Li SM; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2003 May; 25(3):264-7. PubMed ID: 12839691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer?
    Woodman C; Baghdady A; Collins S; Clyma JA
    Br J Obstet Gynaecol; 1997 Feb; 104(2):135-9. PubMed ID: 9070126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.